|Bid||0.00 x 900|
|Ask||0.00 x 1100|
|Day's Range||60.96 - 64.21|
|52 Week Range||40.58 - 73.31|
|Beta (3Y Monthly)||0.32|
|PE Ratio (TTM)||22.29|
|Earnings Date||Aug 7, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||85.00|
FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
The Lynbrook, New York-based company said it had net income of 60 cents per share. The biopharmaceutical company posted revenue of $8.1 million in the period. BioSpecifics shares have risen 13% since the ...
BioSpecifics Technologies (BSTC) will provide updates on Xiaflex and pipeline progress, when it releases first-quarter 2019 results.
Zogenix (ZGNX) receives a Refusal to File letter from the FDA regarding its NDA for Fintepla for the treatment of seizures associated with Dravet syndrome.
United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
On a per-share basis, the Lynbrook, New York-based company said it had profit of 84 cents. The biopharmaceutical company posted revenue of $9.9 million in the period. For the year, the company reported ...
- Positive data from Phase 1 trial of CCH for treatment of uterine fibroids presented at 66th Annual Meeting of the Society for Reproductive Investigation in March 2019 - - 24% year-over-year; 30% quarter-over-quarter ...
Zacks.com featured expert Kevin Matras highlights: Darden Restaurants, Best Buy, BioSpecifics Technologies and ONEOK
BioSpecifics (BSTC) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LYNBROOK, N.Y., March 18, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced with great sadness that Thomas L. Wegman, President of BioSpecifics, passed away on March 13, 2019. Mr. Wegman served as an officer at BioSpecifics for over 20 years and was a member of the Board of Directors since 1994. "It is with great sadness that we report the passing of Tom Wegman.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Anyone researching BioSpecifics Technologies Corp. (NASDAQ:BSTC) might want to considerRead More...
NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
BioSpecifics (BSTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zero-debt allows substantial financial flexibility, especially for small-cap companies like BioSpecifics Technologies Corp. (NASDAQ:BSTC), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...
Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.